

FORM PT01449 (REV. 8-83)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2500.116US1		SERIAL NO. 09/249,529	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANT JAMES D. MARKS et al.			
				FILED February 12, 1999		GROUP 1627	

U. S. PATENT DOCUMENTS									
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE		

O I P F
 JUL 16 1999
 PATENT & TRADEMARK OFFICE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)		
pp	C1	Adams et al., "Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu", British Journal of Cancer, May 1998, Vol. 77, No. 9, pp. 1405-1412.
	C2	Adams et al., "Increased Affinity Leads to Improved Selective Tumor Delivery of Single-Chain Fv Antibodies", Cancer Research, February 1998, Vol. 58, No. 3, pp. 485-490.
	C3	Altenschmidt et al., "Targeted Therapy of Schwannoma Cells in Immunocompetent Rats with an erbB2-Specific Antibody-Toxin", International Journal of Cancer, 26 September 1997, Vol. 73, No. 1, pp. 117-124.
	C4	Hudziak et al., "p185her2 Monoclonal Antibody has Antiproliferative Effects in Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor, Molecular and Cellular Biology, March 1989, Vol. 9, No. 3, pp. 1165-1172.
	C5	Hurwitz et al., "Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake", Proceedings of the National Academy of Sciences, April 11, 1995, Vol. 92, No. 8, 3353-3357.
	C6	Kirpotin et al., "Sterically Stabilized Anti-HER2 Immunoliposomes: Design and Targeting to Human Breast Cancer Cells in Vitro", Biochemistry, January 7, 1997, Vol 36, No. 1, pp. 66-75.
	C7	Lewis et al., "Differential responses of human tumor cell lines to anti-p185her2 monoclonal antibodies", Cancer, Immunology, Immunotherapy, March 1993, Vol 37, No. 4, pp. 255-263.
	C8	Pereira et al., "A model system for detection and isolation of a tumor cell surface antigen using antibody phage display, Journal of Immunological Methods, 11 April 1997, Vol. 203, No. 1, pp. 11-24.
✓	C9	Sheets et al., "Efficient construction of a large nonimmune phage antibody library: The production of high-affinity human single-chain antibodies to protein antigens", Proceedings of the National Academy of Sciences, May 26, 1998, Vol. 95, No. 11, 6157-6162.

EXAMINER <div style="font-family: cursive; font-size: 1.2em; margin-top: 10px;">P. Ponnaluri</div>	DATE CONSIDERED <div style="font-family: cursive; font-size: 1.2em; margin-top: 10px;">7/25/00</div>
--	--

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PT01449
(REV. 8-83)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

2500.116US1

SERIAL NO.

09/249,529

JUL 20 1998

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT

JAMES D. MARKS et al.

TECH CENTER 1600/2900

FILED


February 12, 1999

GROUP

1627

U. S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

PP	C10	Slamon, et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer, American Association for the Advancement of Science, 12 May 1989, Vol. 244, No. 4905, pp. 707-712.
	C11	Stancovski, et al., "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth", Proceedings of the National Academy of Sciences, October 1, 1991, Vol 88, No. 19, pp. 8691-8698.
	C12	Ullrich, et al., "Signal Transduction by Receptors with Tyrosine Kinase Activity", Cell, April 20, 1990, Vol. 61, No. 2, pp. 203-212.
	C13	Yarden, Yosef, "Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active", Proceedings of the National Academy of Sciences, April 1990, Vol 87, No. 7, pp. 2569-2573.
	C14	Watters, et al., "An optimized method for cell-based phage display panning", Immunotechnology, 1997, Vol. 3, pp. 21-29.
	C15	Barry, et al., "Toward cell-targeting gene therapy vectors: Selection of cell-binding peptides from random peptide-presenting phage libraries", Nature Medicine, March 1996, Vol. 2, No. 3, pp. 299-305.
	C16	Fominaya, et al., "Target Cell-specific DNA Transfer Mediated by a Chimeric Multidomain Protein", Journal of Biological Chemistry, May 3, 1996, Vol. 271, No. 18, pp. 10560-10568.
	C17	Hart, et al., "Cell Binding and Internalization by Filamentous Phage Displaying a Cyclic Arg-Gly-Asp-containing Peptide", Journal of Biological Chemistry, April 29, 1994, Vol. 269, No. 17, pp. 12468-12474.
	C18	Larocca et al., "Targeting Bacteriophage to Mammalian Cell Surface Receptor for Gene Delivery", Human Gene Therapy, November 1, 1998, Vol. 9, pp. 2393-2399.
	C19	Marks, et al., "Molecular Evolution of Proteins on Filamentous Phage", Journal of Biological Chemistry, August 15, 1992, Vol. 267, No. 23, pp. 16007-16010.
	C20	Okayama, et al., "Bacteriophage Lambda Vector for Transducing a cDNA Clone Library into Mammalian Cells", Molecular and Cellular Biology, May 1985, Vol. 5, No. 5, pp. 1136-1142.
	C21	Schier, et al., "Identification of functional and structural amino-acid residues by parsimonious mutagenesis", Gene, March 9, 1996, Vol. 169, No. 2, pp. 147-155.
✓	C22	Schier, et al., "Efficient <i>in vitro</i> affinity maturation of phage antibodies using BIAcore guided selections", Hum. Antibod. Hybridomas, 1996, Vol 3, No. 7, pp. 97-105.

EXAMINER

P. Ponnalun

DATE CONSIDERED

7/25/00


* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PT01449
(REV. 8-83)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. Docket NO.
2500.116US1

SERIAL NO.
09/249,529



INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT
James D. Marks et al.

FILED
February 12, 1999

GROUP
~~1643~~-1627

U. S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
PD	B1 5 8 8 5 7 9 3	3/23/99	Griffeths et al.			
PP	B2 5 7 3 3 7 8 2	3/31/98	Dorai et al.			
PP	B3 5 6 9 6 2 3 7	12/9/97	Fitzgerald et al.			

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANS.? (YES/NO)
B4 9 4 2 6 7 8 7	11/24/94	PCT WO WIPD			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

PP	B5	Larocca et al. (1999) "Gene Transfer to Mammalian Cells Using Genetically Targeted Filamentous Bacteriophage," <i>FASEB Journal</i> , 13(6):727-734
	B6	PCT/US99/07395, International Search Report, August 1999
	B7	PCT/US99/07398, International Search Report, August 1999
	B8	PCT/US99/08468, International Search Report, August 1999

EXAMINER

[Signature]

DATE CONSIDERED

7/25/00

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.